Aclaris Therapts (ACRS) Stock Price, Quote & News

Latest News on ACRS

Mar 4, 2025, 7:00 AM EST - 7 weeks ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 12, 2025, 6:50 AM EST - 2 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 3 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 3 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 23, 2024, 1:41 PM EST - 4 months ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Nov 26, 2024, 4:30 PM EST - 5 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:27 PM EST - 5 months ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 18, 2024, 8:50 AM EST - 5 months ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:10 AM EST - 5 months ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 5 months ago

Aclaris Therapeutics Announces $80 Million Private Placement

Sep 17, 2024, 7:00 AM EDT - 7 months ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 8 months ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Jul 16, 2024, 4:01 PM EDT - 10 months ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jun 25, 2024, 12:36 PM EDT - 10 months ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 6, 2024, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Jan 10, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Provides Corporate Update

Dec 5, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Nov 13, 2023, 7:19 AM EST - 1 year ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Oct 3, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Sep 28, 2023, 7:18 AM EDT - 1 year ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 20, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 18, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aug 7, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jul 11, 2023, 7:31 PM EDT - 1 year ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Jun 13, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Jun 2, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

May 8, 2023, 11:56 AM EDT - 2 years ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

May 8, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 2, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 9, 2023, 7:30 AM EST - 2 years ago

Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa

Feb 23, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Feb 9, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Jan 10, 2023, 4:04 PM EST - 2 years ago

Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower

Jan 6, 2023, 7:01 AM EST - 2 years ago

Aclaris Therapeutics Provides 2023 Outlook

Nov 29, 2022, 7:00 AM EST - 2 years ago

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

Nov 22, 2022, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Key Leadership Transitions

Nov 10, 2022, 4:01 PM EST - 2 years ago

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

Nov 8, 2022, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Sep 27, 2022, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

Aug 30, 2022, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Aug 25, 2022, 7:00 AM EDT - 2 years ago

Market Cap	137.52M
Revenue (ttm)	18.72M
Net Income (ttm)	-132.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-705.50%
Debt to Equity Ratio	0.00

Volume	508,800
Avg Vol	949,084
Day's Range	N/A - N/A
Shares Out	108.28M
Stochastic %K	93%
Beta	0.53
Analysts	Strong Sell
Price Target	$9.83